Compare AMRX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | MIRM |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.2B |
| IPO Year | 2018 | 2019 |
| Metric | AMRX | MIRM |
|---|---|---|
| Price | $21.23 | $91.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $24.29 | ★ $157.71 |
| AVG Volume (30 Days) | ★ 3.5M | 559.1K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.89 | 74.59 |
| EPS | ★ 0.29 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $6.38 | $37.65 |
| Revenue Next Year | $9.21 | $21.04 |
| P/E Ratio | $73.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.39 | $63.23 |
| 52 Week High | $22.07 | $130.00 |
| Indicator | AMRX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 56.52 |
| Support Level | $18.90 | $87.38 |
| Resistance Level | $21.21 | $98.34 |
| Average True Range (ATR) | 0.86 | 4.15 |
| MACD | 0.04 | 0.73 |
| Stochastic Oscillator | 71.96 | 60.16 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.